Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Change in Accured Expenses (2016 - 2022)

Edesa Biotech's Change in Accured Expenses history spans 10 years, with the latest figure at -$3.4 million for Q3 2022.

  • For Q3 2022, Change in Accured Expenses fell 772.49% year-over-year to -$3.4 million; the TTM value through Sep 2022 reached $882843.0, up 807.84%, while the annual FY2025 figure was -$715499.0, 4167.65% down from the prior year.
  • Change in Accured Expenses for Q3 2022 was -$3.4 million at Edesa Biotech, down from $2.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.6 million in Q1 2021 and bottomed at -$3.6 million in Q2 2021.
  • The 5-year median for Change in Accured Expenses is $46854.5 (2018), against an average of $4475.0.
  • The largest annual shift saw Change in Accured Expenses crashed 31702.23% in 2019 before it soared 3742.49% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at -$38483.0 in 2018, then skyrocketed by 555.52% to $175298.0 in 2019, then plummeted by 483.48% to -$672234.0 in 2020, then surged by 142.52% to $285825.0 in 2021, then tumbled by 1301.87% to -$3.4 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Change in Accured Expenses are -$3.4 million (Q3 2022), $2.5 million (Q2 2022), and $1.6 million (Q1 2022).